ADVOCACY LETTERS
- NICA Letter to BCBS SC Entyvio
- Nyquist Response Tezspire Letter August, 2022
- NICA Tezspire-Letter-Sad-List
- Build Back Better Comment Letter July, 2022
- Pharmaceutical Task Force, Project No. P212900
- OIG Safe Harbor Comment Letter Feb. 2022 – National Infusion Center Association
- Comments on PREVENT Pandemics Act
- Comment letter to CMS RE: MACRA
- Comment letter to U.S. Pharmacopeia (USP) RE: USP Medicare Model Guidelines
- Comment letter to Palmetto GBA RE: Down-coding admin codes for biologics
- Comment letter to CMS RE: Medicare Part B Prescription Drug Models
- Memorandum in Support of S6303 and A8246
- Letter to UnitedHealthcare RE: Updating formulary to switch beneficiaries to an insurer-preferred product for reasons unrelated to health or safety
- Letter to Health Alliance Plan of Michigan RE: Step Therapy Policy
- Letter to Regence BlueShield of Washington RE: Step Therapy Policy
- Letter to BlueCross BlueShield of Michigan RE: revising the prior authorization medical coverage drug list guidelines
- Letter to BlueCross BlueShield of Tennessee RE: Specialty Pharmacy Mandate
- Letter to UnitedHealthcare RE: Step therapy, specialty pharmacy mandate, and non-medical switching (4/15/2020)
- Letter to Arkansas BlueCross BlueShield RE: self-administration medication policy (7/29/2020)
POSITION PAPERS
NICA believes health plans should consider Step Therapy policies for drugs only when reasonable according to the following criteria – when the Cost of failure is LOW, the TIME to fail is SHORT, and the clinical RISK of failing preferred drugs is LOW.
Read our Step Therapy position paper HERE and visit our Step Therapy advocacy page to learn how you can get involved.